Immunogenicity assessment during the development of protein therapeutics.

about

Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.Development and characterization of an anti-rituximab monoclonal antibody panel.Modular pore-forming immunotoxins with caged cytotoxicity tailored by directed evolution

P2860

Q50034109-2D4F1D4B-06D1-407A-A221-6B9222E3262C Q50140061-CEE16DFB-6DE9-4D24-B97B-F552E8F298C1 Q56872060-B4AC12CA-8F35-44AF-A0DB-E76433E05205

P2860

Immunogenicity assessment during the development of protein therapeutics.

Item

http://www.wikidata.org/entity/Q47855368

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Immunogenicity assessment during the development of protein therapeutics.

@en

Immunogenicity assessment during the development of protein therapeutics.

@nl

type

Item

label

Immunogenicity assessment during the development of protein therapeutics.

@en

Immunogenicity assessment during the development of protein therapeutics.

@nl

prefLabel

Immunogenicity assessment during the development of protein therapeutics.

@en

Immunogenicity assessment during the development of protein therapeutics.

@nl

P1476

Immunogenicity assessment during the development of protein therapeutics.

@en

P2093

Amy S Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach

Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay

Development of immune-specific interaction potentials and their application in the multi-agent-system VaccImm.

The MHC class I antigen presentation pathway: strategies for viral immune evasion.

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications.

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.

P304

584-594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JPHP.12810

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zuben E Sauna

P577

2017-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28872677

http://www.w3.org/2001/XMLSchema#string

Immunogenicity assessment during the development of protein therapeutics.

about

P2860

P2860

Immunogenicity assessment during the development of protein therapeutics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698